Lori Frederick

2.5k total citations · 1 hit paper
22 papers, 1.7k citations indexed

About

Lori Frederick is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Lori Frederick has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Lori Frederick's work include Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Lori Frederick is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Lori Frederick collaborates with scholars based in United States and India. Lori Frederick's co-authors include C. David James, Greg Eley, Xiao Yang Wang, Benjamin Alderete, Deanne Hebrink, Daniel W. Fults, R Jenkins, O. Raffel, Robert B. Jenkins and Alan P. Fields and has published in prestigious journals such as Blood, Oncogene and Human Pathology.

In The Last Decade

Lori Frederick

22 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

2000 529 citations Lori Frederick, Greg Eley et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lori Frederick United States	15	1.1k	646	523	287	264	22	1.7k
Kenji Tada Japan	15	829 0.8×	639 1.0×	284 0.5×	319 1.1×	242 0.9×	23	1.7k
Guido Reifenberger Germany	21	1.1k 1.0×	546 0.8×	443 0.8×	270 0.9×	188 0.7×	26	2.1k
Sergey Popov United Kingdom	20	825 0.7×	358 0.6×	316 0.6×	349 1.2×	173 0.7×	48	1.5k
Sandra H. Bigner United States	11	781 0.7×	660 1.0×	423 0.8×	297 1.0×	121 0.5×	11	1.5k
Andréï Tchirkov France	22	702 0.6×	479 0.7×	389 0.7×	412 1.4×	174 0.7×	88	1.7k
Aniello Cerrato Italy	24	957 0.9×	249 0.4×	668 1.3×	325 1.1×	121 0.5×	33	1.7k
Karisa C. Schreck United States	16	946 0.9×	505 0.8×	418 0.8×	290 1.0×	107 0.4×	55	1.4k
Sylvia Kocialkowski United Kingdom	11	862 0.8×	1.2k 1.9×	235 0.4×	518 1.8×	206 0.8×	13	1.8k
Jens Koopmann United States	14	777 0.7×	535 0.8×	718 1.4×	494 1.7×	69 0.3×	15	1.9k
Britta Blaschke Germany	14	904 0.8×	655 1.0×	219 0.4×	306 1.1×	90 0.3×	15	1.5k

Countries citing papers authored by Lori Frederick

Since Specialization

Citations

This map shows the geographic impact of Lori Frederick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Frederick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Frederick more than expected).

Fields of papers citing papers by Lori Frederick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Frederick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Frederick. The network helps show where Lori Frederick may publish in the future.

Co-authorship network of co-authors of Lori Frederick

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Frederick. A scholar is included among the top collaborators of Lori Frederick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Frederick. Lori Frederick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oliveira, Jennifer L., Lori Frederick, Mrinal M. Patnaik, et al.. (2018). Genotype–phenotype correlation of hereditary erythrocytosis mutations, a single center experience. American Journal of Hematology. 93(8). 1029–1041. 33 indexed citations

Fang, Hong, Prashant Kapoor, Wilson I. Gonsalves, et al.. (2018). Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology. 150(2). 168–176. 6 indexed citations

King, Rebecca L., Wilson I. Gonsalves, Stephen M. Ansell, et al.. (2016). Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology. 145(6). 843–851. 32 indexed citations

Pulido, José S., Diva R. Salomão, Lori Frederick, & David S. Viswanatha. (2015). MyD-88 L265P MUTATIONS ARE PRESENT IN SOME CASES OF VITREORETINAL LYMPHOMA. Retina. 35(4). 624–627. 23 indexed citations

Oliveira, Jennifer L., Lori Frederick, Mrinal M. Patnaik, et al.. (2015). Spectrum of Mutations Associated with Hereditary Erythrocytosis. Blood. 126(23). 2140–2140. 2 indexed citations

Frederick, Lori, et al.. (2014). Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm. Human Pathology. 45(8). 1784–1789. 5 indexed citations

Zent, Clive S., Ronald P. Taylor, Margaret A. Lindorfer, et al.. (2014). Chemoimmunotherapy for relapsed/refractory and progressive 17p13‐deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low‐dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. American Journal of Hematology. 89(7). 757–765. 32 indexed citations

Raza, Sania S., David S. Viswanatha, Lori Frederick, et al.. (2011). TP53 mutations and polymorphisms in primary myelofibrosis. American Journal of Hematology. 87(2). 204–206. 15 indexed citations

Frederick, Lori, Lee Jamieson, Verline Justilien, et al.. (2008). Matrix metalloproteinase-10 is a critical effector of protein kinase Cι-Par6α-mediated lung cancer. Oncogene. 27(35). 4841–4853. 78 indexed citations

10.

Fields, Alan P., Lori Frederick, & Roderick P. Regala. (2007). Targeting the oncogenic protein kinase Cι signalling pathway for the treatment of cancer. Biochemical Society Transactions. 35(5). 996–1000. 53 indexed citations

11.

Krishnan, Sunil, et al.. (2007). Inhibitory Effect of Pirfenidone on Glioblastoma Cell Lines: Implications for Treatment of Neurofibromatosis. 7(1). 58–68. 2 indexed citations

12.

Frederick, Lori, et al.. (2000). Diversity and frequency of EGFR mutations in human glioblastomas. 41. 357. 1 indexed citations

13.

Frederick, Lori, et al.. (2000). Analysis of genomic rearrangements associated with EGFRvIII expressionsuggests involvement of Alu repeat elements. Neuro-Oncology. 2(3). 159–163. 64 indexed citations

14.

James, C. David, Evanthia Galanis, Lori Frederick, et al.. (1999). Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.. International Journal of Oncology. 15(3). 547–53. 42 indexed citations

15.

Raffel, Corey, Lori Frederick, Judith R. OʼFallon, et al.. (1999). Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations.. PubMed. 5(12). 4085–90. 100 indexed citations

16.

Eley, Greg, et al.. (1998). 3′ End structure and rearrangements ofEGFR in glioblastomas. Genes Chromosomes and Cancer. 23(3). 248–254. 10 indexed citations

17.

Smith, Jeremy C., et al.. (1998). Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene. 16(2). 191–195. 27 indexed citations

18.

Raffel, O., R Jenkins, Lori Frederick, et al.. (1997). Sporadic medulloblastomas contain PTCH mutations.. PubMed. 57(5). 842–5. 439 indexed citations

19.

Frederick, Lori, et al.. (1997). PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.. PubMed. 57(23). 5254–7. 163 indexed citations

20.

Lust, John A., Diane F. Jelinek, Kathleen A. Donovan, et al.. (1995). Sequence, Expression and Function of an mRNA Encoding a Soluble Form of the Human Interleukin-6 Receptor (sIL-6R). Current topics in microbiology and immunology. 194. 199–206. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact